



25-26 November 2019 | Maritim Hotel, Berlin

An application has been made to the EACCME® for CME accreditation of this event

Monday, 25 November 2019- Day 1

08.00-9.00 Registration

Welcome

Plenary Room

09.00-09.05 Welcome

Hans-Dieter Volk, Petra Reinke

Plenary Room

09.05-09.40 Introduction

RESTORE – Health by Advanced Therapies – Opportunities and Challenges Hans-Dieter Volk

Opening Remarks of Ada Yonath, Nobel Prize for Chemistry Director of Weizmann Institute of Science, Israel

Session 1 Foundational Research (new targets and new indications)

Maximilian Emmert- University Zurich, Switzerland

Chair: to be added

Plenary Room

09.40-10.05	On the way to improved therapies for skin diseases and disorders (20 + 5 min discussion) Alexandra Marques - University of Minho, Portugal
10.05-10.20	Targeting the tumour vasculature with CAR-T cells for treatment of solid tumours (10 + 5 min discussion) Andrea Keogh- Catapult, United Kingdom
10.20-10.50	Coffee Break & Posters set up
10.50-11.05	Characterizing immune cells by Single-Cell-Sequencing - Identification of novel therapeutic targets for precision cell therapy in chronic inflammation (10 + 5 min discussion) Mir-Farzin Mashreghi- DRFZ, Germany
11.05-11.20	Bioengineered implants to repair the heart (10 + 5 min discussion)

IST ADVANCED THERAPIES SCIENCE MEETING



25-26 November 2019 | Maritim Hotel, Berlin



11.20-11.35 Immunobiology of CarT cells and adoptive T cell therapy of cancer and autoimmune diseases (10 + 5 min discussion) Maksim Mamonkin-affiliation to be added 11.35-11.45 **Break** Session 2 Preclinical Models and Technologies (focus on human-on-a-chip) Chair: to be added Plenary Room 11.45-12.10 Engineered polymeric matrices as instructive cells' artificial micro-environment (20+ 5 min discussion) Antonella Motta - University of Trento, Italy Stimuli-responsive and multifunctional scaffold-cells systems for tendon tissue regeneration (20+ 12.10-12.45 5 min discussion) Manuela Gomes - University of Minho, Portugal From Organ-on-a-Chip Tools Towards Patients on Chips - Enforcing a Paradigm Shift in 12.45-13.00 **Drug Development** (10 + 5 min discussion) Uwe Marx- TissUse, Germany 13.00-13.15 Monitoring CAR T cell efficacy in fresh human solid tumor slices (10 + 5 min discussion) Emmanuel Donnadieu-Inserm, France 13.15-13.20 **Break** 13.20-13.30 Photo session 13.30-14.30 Lunch & poster setup finalization Session 3 Manufacturing Technologies (including product characterisation and

automation)

Chair: to be added

Plenary Room

Engineering personalized tissue implants: From 3D printing to bionic tissues (20+ 5 min 14.30-14.55 discussion) Tal Dvir - Tel Aviv University, Israel

Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of 14.55-15.20 **Immune Function** (20+ 5 min discussion)



European Horizon 2020
European Union funding for Research & Innovation

25-26 November 2019 | Maritim Hotel , Berlin

17.50-18.00

based constructs

	Eric Shifrut - University of California, San Francisco, United States	
15.20-15.35	Becoming cell therapy Makers - Opportunities and challenges in manufacturing of cell therapy products (10 + 5 min discussion) Lior Raviv - Pluristem, Israel	
15.35-15.50	Pioneering Cell Processing of personalized ATMPs (10 + 5 min discussion) Michael Apel - Miltenyi, Germany	
15.50-16.05	Generation of hematopoietic cells with lymphoid potential from induced pluripotent stem cells (iPSC) for adoptive immunotherapy of cancer and leukemia (10 + 5 min discussion) Annelise Bennaceur - INSERM, France	
16.05-16.20	Functional Surfaces and Scaffolds Combined with Stem Cells for Bone and Cartilage Tissue Engineering (10 + 5 min discussion) Nuno Neves - University Minho, Portugal	
16.20-16.30	Break	
Break out sessions in Plenary and break-out rooms for topics 1-3 (10 minutes each) 1 Foundational Research (new targets and new indications) (Plenary)		
16.30-16.40	Developing Novel siRNA Nanoparticle Therapies For Cystic Fibrosis by Silencing of the Epithelial Sodium Channel Stephen Hart - UCL Great Ormond Street Institute of Child Health, UK	
16.40-16.50	Epigenetic control of T cell differentiation: From genome-wide signatures to local regulators and their targeted manipulation. Julia K. Polansky - BCRT Charité, Germany	
16.50-17.00	Subconjunctival injection of low-dose mesenchymal stem cells promotes corneal allograft survival in a mouse cornea transplantation model Thomas Ritter - National University of Ireland Galway, Ireland	
17.00-17.10	Immunomodulatory properties of amniotic membrane derivatives for tissue regeneration: a 20-year experience Ornella Parolini - Università Cattolica Santo Cuore, Italy	
17.10-17.40	Coffee Break	
17.40-17.50	Pre-activated mesenchymal stromal cells induce regulatory immune populations in vivo and prolong corneal allograft survival Thomas Ritter - National University of Ireland Galway, Ireland	

Treatment of osteochondral defects of the knee in rats using bilayered scaffold free cell-



25-26 November 2019 \mid Maritim Hotel , Berlin



	Luis Freitas Mendes - KULEUVEN, Belgium
18.00-18.10	Highly activated Natural Killer cells to treat pediatric cancer Maria Vela - Hospital La Paz Institute for Health Research (IdiPAZ), Spain
18.10-18.20	Neural precursor/stem cell-based therapy for Rett syndrome Nicoletta Landsberger - University of Milan, Italy
18.20-18.30	Drive regeneration by employing the immune-structure interface Georg Duda - BCTR Charité, Germany
2 Preclinical Models and Technologies (focus on human-on-a-chip) (Berlin D or London)	
16.30-16.40	Tissue engineered mimetic autografts for bone regeneration Froilán Granero-Moltó - Clínica Universidad de Navarra, Spain
16.40-16.50	A millifluidic dynamic system to unveil the interaction among breast cancer cells, fibroblasts and mesenchymal stem cells Virginia Brancato, University of Minho, Portugal
16.50-17.00	Aryl hydrocarbon receptor- driven immunometabolic checkpoints in type-1 dendritic cells restrains antitumor responses Francesca Fallarino - Università di Perugia, Italy
17.00-17.10	Amniotic mesenchymal stromal cell secretome: a potent pleiotropic strategy for acute brain injury Francesca Pischiutta - Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
17.10-17.40	Coffee Break
17.40-17.50	Immunosuppressant-resistant T cells for advanced adoptive T cell therapy in immunosuppressed patients Laila Amini, BCRT- Charité, Germany
17.50-18.00	Adapter CAR T cells - A new versatile platform for controllable CAR T cell function Joerg Mittelstaet, Miltenyi Biotec GmbH,Germany
18.00-18.10	Microvessels-on-Chip - Bridging the gap between blood and lymph Barbara Bachmann, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology and Vienna University of Technology, Austria
18.10-18.20	MSC improve skeletal muscle regeneration via locally damplen the pro-inflammatory capacity of CD8+ T cell subpopulations Sven Geissler, BCRT Charité, Germany
18.20-18.30	Treatment of a naturally occurring dog model of Alport Syndrome by means of CRISPR/Cas9 gene therapy approach. Sergio Daga, University of Siena, Medical Genetics, Italy

IST ADVANCED THERAPIES SCIENCE MEETING



25-26 November 2019 | Maritim Hotel , Berlin



18.30-18.40	Effectiveness and safety of adoptive cell therapy with regulatory type 1 (Tr1) cells in pancreatic islet transplantation Georgia Fousteri, San Raffaele Diabetes Research Institute, Italy
18.40-18.50	A preclinical non-human primate model to investigate the regenerative potential of human induced pluripotent stem cell-derived cardiomyocytes Ina Gruh, Hannover Medical School, Germany
3 Manufac automation)	cturing Technologies (including product characterisation and (Berlin D or London)
16.30-16.40	Tissue Manufacturing by Bioprinting: Challenges and Opportunities for Regenerative Medicine Fabien Guillemot - Poietis, France
16.40-16.50	Self-assembly of stem/progenitor cells creates human neo-vascularized skin and skin organoids Patricia Peking - Paracelsus Medical University, Austria
16.50-17.00	Using clinical data for manufacturing design and release criteria to improve the quality of a cell-based ATMP for cartilage repair Giulietta Roel, - CO.DON AG, Germany
17.00-17.10	Harmonisation of multicenter MSC production for a phase III clinical trial Melissa Van Pel - Leiden University Medical Center, Netherlands
17.10-17.40	Coffee Break
17.40-17.50	Manufacturing of stem cell derived in-vitro tissues using robot technology Marco Metzger - Fraunhofer Institute for Silicate Research (ISC), Germany
17.50-18.00	EU Project CARAT: Chimeric Antigen Receptors (CARs) for Advanced Therapies Michael Apel, - Miltenyi Biotec GmbH, Germany
18.00-18.10	Human induced pluripotent stem cells from universal donors as starting material for regenerative therapies Micha Drukker, Helmholtz Center Munich, Germany
18.10-18.20	Gene therapy getting personal: mutation-specific editing and gene addition strategies Carsten Werner Lederer, The Cyprus Institute of Neurology and Genetics / TEDDY, Cyprus
18.20-18.30	T cell immunity toward CRISPR-associated nucleases Dimitrios Laurin Wagner, Charité, Germany
18.30-18.40	Tissue-Engineered ATMPs for cartilage healing Oliver Pullig, Fraunhofer Translational Center Regenerative Therapies - TLC-RT, Germany





25-26 November 2019 | Maritim Hotel , Berlin

18.40-18.50	Decentralised manufacturing using the automated CliniMACS Prodigy platform for a multicenter clinical trial in Germany Michael Apel, Miltenyi Biotec GmbH, Germany
18.50-19.00	Personalized therapy for TP53 mutated cancer patients based on CRISPR-Cpf1 and suicide gene delivery Filomena T. Papa, University of Siena, Italy
19.00-19.10	Generation, cultivation and characterization of stem cell-derived bioartificial cardiac tissue of clinically relevant dimensions Ina Gruh, Hannover Medical School, Germany

Poster session & Networking Get-Together

19.30-21.00	Poster session & discussion with Cheese & Wine buffet
21.00-22.00	Poster session continued

Tuesday, 26 November 2019- Day 2

Introduction Day 2

Plenary Room

08.30-08.45 Registration for arrival day 2

08.45-09.00 Hans-Dieter Volk (15 min)

Session 4 Clinical Implementations (including reimbursement models)

Chair: to be added

Plenary Room

09.00-09.25	Epithelial stem cell-mediated gene therapy (20 + 5 min discussion) Michele De Luca - University of Modena, Italy
09.25-09.50	Clinical implementation of cornea and skin artificial tissues generated with fibrin-agarose biomaterials (20 + 5 min discussion) Antonio Campos - University of Granada, Spain
09.50-10.15	Improving the expansion and persistence of tumor-specific T-cells targeting immunosuppressive tumors (20 + 5 min discussion) Cliona M. Rooney - Baylor College of Medicine, Houston, United States



European Horizon 2020
European European Union funding for penarch & Innovation

25-26 November 2019 \mid Maritim Hotel , Berlin

10.15-10.30	Reshape immune balance by next-generation regulatory T cells (10 + 5 min discussion) Petra Reinke - BeCAT Charité Germany
10.30-10.45	Cellular therapy: Boosting innovation in technology and clinical translation (10 + 5 min discussion) Michael Apel - Miltenyi Biotech GmbH Germany
10.45-11.00	Development of allogeneic Placenta-derived (PLX) cell therapy- from bench- to bedside (10 + 5 min discussion) Racheli Ofir - Pluristem, Israel
11.00-11.15	Car-T cell therapy- a clinical experience report (10 + 5 min discussion) Michal Besser- affiliation to be added
11.15 -12.00	Coffee Break

Session 5 Regulatory Science & Clinical Trials Chair:

Plenary Room

12.00-12.25	Role of the EMA Committee for Advance Therapies (CAT) in the assesment of ATMPs (20+5 min discussion) Paolo Gasparini - University of Trieste, IRCCS, Italy
12.25-12.50	MSCs as a therapy for diabetic complications: a translational journey in the EU (20+ 5 min discussion) Timothy O'Brien
12.50-13.05	An Integrated Eco-System of Research and Development for Orphan Medicinal Products: the IRDiRC Orphan Drug Development Guidebook (10+ 5 min discussion) Michela Gabaldo - Fondazione Telethon, Italy

13.05-13.10 Break

13.10-14.15 Lunch

Session 6 Big data- Al-Ethics Economics Chair:

Plenary Room

14.15-14.30 State and potential for data-driven strategies in the cell and gene therapy industry (10+ 5 min discussion)

Marc-Olivier Baradez - Catapult, United Kingdom



European Horizon 2020
European Union funding for Research & Innovation

25-26 November 2019 | Maritim Hotel , Berlin

14.30-14.45	Ethics management of science and the public (10+ 5 min discussion) Andreas Kurtz - Charité, Germany
14.45-15.00	Ethics in scientific communication (10+ 5 min discussion) Pier- Maria Fornasari
15.00-15.15	A Consistent Mechanism for Designing a Clinical Trial based on Al Technologies Applied to Observational Cohort (10 + 5 min discussion) Michal Rosen-Zvi - IBM Research, Israel
Short talks	
15.15-15.25	In silico regenerative medicine: from living implants to digital patients and back again (8 + 2 min discussion) Liesbeth Geris - KU Leuven, Belgium
15.25-15.35	Stem cell data standards and data utility (8 + 2 min discussion) Andreas Kurtz - Charité, Germany
15.35-15.45	Break

Break out sessions in Plenary and break-out rooms for topics 4-5 (10 minutes each)

4 Clinical Implementations (including reimbursement models) (Plenary)

15.45-15.55	Stem cells for treatment of Amyotrophic lateral sclerosis. Eva Sykova - Scimed Biotechnologies, Czech Republic
15.55-16.05	Chimeric antigen receptor (CAR) immunotherapy for patients with solid tumors Gabriele Pecher - Charité, Germany
16.05-16.15	SLAMF7 CAR-T cells for immunotherapy of multiple myeloma: 'real-world' experience of GMP-manufacturing using virus-free Sleeping Beauty gene-transfer Michael Hudecek - Universitätsklinikum Würzburg, Germany
16.15-16.25	Cartilage regeneration with ATMP produced cells; past, present and future pertspectives Anders Lindahl - Institute of Biomedicine, University of Gothenburg, Sweden
16.25-16.35	Adoptive Transfer of Thymic Derived Regulatory T-Cells in Therapy-Refractory Chronic Graft versus Host Disease in Children Sybille Landwehr-Kenzel, Charité, Germany

5 Regulatory Science & Clinical Trials (Berlin D or London)



25-26 November 2019 | Maritim Hotel , Berlin

15.45-15.55	Technology Maturation Platform, Public-Private Partnerships, bench-to-bedside translational development
	Roke Iñaki Oruezabal - Andalusian Network for Design and Translation of Advanced Therapies, Spain
15.55-16.05	Translation of CAR-based innovation into clinics: how to overcome regulatory hurdles
	Michael Apel, - Miltenyi Biotec GmbH, Germany
16.05-16.15	Personalized tissue-engineered grafts Raimund Strehl - Verigraft AB, Sweden
16.15 -16.25	Placental Cell Therapy for the Treatment of Muscle Trauma: From Preclinical Models to Clinical Phase III Tobias Winkler - Charité, Germany
16.40-17.40	Poster session & Coffee Break
Final Remai	rks, Farewell (Plenary)

17.40-18:00 Final Remarks, Farewell

18:00 End of meeting